Drug Profile
Research programme: anti-thrombotic compounds - Ception Therapeutics
Latest Information Update: 27 May 2010
Price :
$50
*
At a glance
- Originator Ception Therapeutics
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Jan 2007 Preclinical trials in Thrombosis in USA (unspecified route)